Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has entered into a material agreement with a biotechnology company developing genetic medicines.
ProBioGen’s Transposase binds to specific epigenetic histone marks characteristic for highly active genome regions. Omitting the plasmid backbone, multiple transposable elements carrying the transgene cassette are specifically inserted resulting in highly stable and high expressing clones.
On 1 December 2023, Ana-Maria Šimundić took up the newly created position as director of Global Medical & Clinical Affairs at Greiner Bio-One. In this role, she will represent Greiner Bio-One in national and international professional circles as well as foster exchange with experts in science and the field. Her area of responsibility includes all […]
Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates. This research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology with the goal of bringing more medicines to patients.
Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site. The site will feature a new state-of-the-art genomics lab scheduled to begin full operations in March this year.
MIMETAS, a leader in human 3D disease modelling, and Yamaha Motor Co., a developer of the Cell Handler, have singed a strategic joint marketing agreement aimed at advancing therapeutic development using human-relevant models throughout the early drug development pipeline. The collaboration combines MIMETAS’ comprehensive disease modelling and assay development expertise with Yamaha Motor’s state-of-the-art Cell […]
CN Bio, a leading Organ-on-a-Chip (OOC) company, says its PhysioMimix assay for Non-alcoholic steatohepatitis (NASH) was important for confirmation of efficacy for INI-822 from Inipharm.
Verici Dx, a developer of advanced clinical diagnostics for organ transplant, has signed an exclusive global licensing agreement with Thermo Fisher Scientific to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.
Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease
Nanologica expands its product portfolio of purification medias for preparative chromatography and has received a trial order worth approximately MSEK 3.6 from a customer in Asia.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.